



## Jenburkt Pharmaceuticals Limited

Regd. Office: Nirmala Apartments, 93, Jayprakash Road, Andheri West, Mumbai-400 058.

Telephone No.: 022-67 603 603 | Email ID: investor@jenburkt.com,

CIN: L24230MH1985PLC036541 | Website: [www.jenburkt.com](http://www.jenburkt.com)

### **“Saksham Niveshak”: 100 Days Campaign - IEPF 28<sup>th</sup> July, 2025 to 6<sup>th</sup> November, 2025**

#### **Update Your Details and Claim Your Dividends**

As per Section 124 and 125 of the Companies Act, 2013, any dividend that remains unclaimed/unpaid for 7 consecutive years, along with the corresponding shares, is liable to be transferred to the Investor Education and Protection Fund (IEPF).

SEBI has vide its Circulars no. SEBI/HO/MIRSD/MIRSD\_RTAMB/P/CIR/2021/655 dated 3<sup>rd</sup> November, 2021, and subsequent circulars issued from time to time, mandated updating of KYC details and processing investor service requests.

In line of the above and as a part of the Investor Education and Protection Fund Authority (IEPFA), initiative the Company has launch a **100 Days Campaign - "Saksham Niveshak" from 28<sup>th</sup> July, 2025 to 6<sup>th</sup> November, 2025.**

#### This campaign aims to:

- Facilitate to update the KYC details, including PAN (linked with Aadhaar), email ID, mobile number, nominee details, and complete bank account details (with IFSC, MICR code, etc.);
- Assist shareholders in claiming unclaimed dividends (if any) directly from the Company;
- Prevent unnecessary transfer of dividends and shares to the IEPF.
- Receive all your future dividends by electronic mode i.e. direct credit in to your bank account and also to receive all future communication by e-mail.

#### Action Required from Shareholder:

- **in case of demat shareholding:** Update your complete and correct KYC details with your Depository Participant (DP) and Submit a self-attested updated Client Master List (CML) to the Company or its Registrar & Share Transfer Agent (RTA) on or before 6<sup>th</sup> November 2025.
- **in case of physical shareholding:** submitting duly filled and signed forms ISR-1, ISR-2, ISR-3 (for opting out of nomination), SH-13 or SH-14 with the required documents to the Company or its Registrar & Share Transfer Agent (RTA) on or before 6<sup>th</sup> November 2025.  
(forms can be download from the website of the Company viz. [www.jenburkt.com](http://www.jenburkt.com) or its RTA viz. [www.Bigshareonline.com](http://www.Bigshareonline.com).)
- **Dematerialise your physical shares.**

Since dividend on shares is only payable in electronic mode, dividend will only be credited in shareholder's bank account AFTER updating the above information / documents.

RTA: M/s. Bigshare Services Pvt. Ltd., Office No: S6-2, 6<sup>th</sup> Floor, Pinnacle Business Park, Next to Ahura Centre, Mahakali Caves Road, Andheri (East), Mumbai- 400093.

Contact Person: Ms. Charmi Rajdev | E-mail: [charmi@bigshareonline.com](mailto:charmi@bigshareonline.com)

Tel. No.: +91-22-62638200, 62638222/23 | Website: <https://www.bigshareonline.com/>

#### **Mode of dispatch of Documents :**

- By post: Physical copies, self-attested and dated or;
- By email: from your registered email ID to [charmi@bigshareonline.com](mailto:charmi@bigshareonline.com) or;
- Online: Upload at RTA's portal:
  - **i-connect:** <https://iconnect.bigshareonline.com/Account/Login>
  - **Investor's Query:** <https://www.bigshareonline.com/Investorlogin.aspx>

If you need any assistance or have questions, please feel free to reach out to us.

Yours faithfully,

For Jenburkt Pharmaceuticals Limited,

Sd/-

Ashish R. Shah

Company Secretary